Company / Return on Assets (ROA)
ADMA Biologics, Inc. Return on Assets (ROA) History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Return on Assets (ROA)
23.5%
FY2025
5-year range
-25.9% / 40.5%
FY2021-FY2025
Trend
-41.8%
vs FY2024
Sector context
#9 of 213
Health Care
What the data says
Among 213 Health Care companies, ADMA Biologics, Inc. is in the top 4% for return on assets (roa). Return on Assets (ROA) has fluctuated over the past 10 years, ranging from -82.4% in FY2016 to 40.5% in FY2024.
Based on SEC 10-K filings.
23.5% in FY2025 with a 5-year CAGR of +60.0%. Top quartile in the Health Care sector.
Improved from -8.6% to 23.5% over the past 2 years.
Health Care sector context is included.
Return on Assets (ROA) over time
Growth rates
- 3-Year Change
- +49.5pp
- 5-Year Change
- +60.0pp
- 10-Year Change
- -
Sector benchmark
+197.4% above sector average
Key checks
Key Insights
- In FY2025, return on assets (roa) decreased 41.8% year-over-year.
- Currently 47.7pp above the Health Care sector average.
- Peak return on assets (roa) was recorded in FY2024.
- Lowest return on assets (roa) in the period was in FY2016.
Company context
Key Data Points
- Altman Z-Score 3.37 (safe zone, above 2.9 threshold)
- Strong profit margin: 46.4%
- Low earnings quality (accrual-heavy earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Return on Assets (ROA)Value | YoY GrowthYoY |
|---|---|---|
| FY2025 | 23.5% | -41.8% |
| FY2024 | 40.5% | +571.4% |
| FY2023 | -8.6% | +66.9% |
| FY2022 | -25.9% | +0.0% |
| FY2021 | -25.9% | +28.9% |
| FY2020 | -36.5% | +4.0% |
| FY2019 | -38.0% | +48.6% |
| FY2018 | -74.0% | -309.4% |
| FY2017 | -18.1% | +78.1% |
| FY2016 | -82.4% | -16.2% |
As of FY2025 · SEC 10-K · Updated Jul 1, 2026